Parikshit Somani's Four Years and the Assembly Line of Contamination Defenses in Tennis

Three Phrases That Ended a Career

At a hearing held in August, the independent tribunal of the International Tennis Integrity Agency (ITIA) produced three phrases to describe Parikshit Somani's explanation: "scientifically implausible," "highly speculative," and "unconvincing." On Wednesday, the ITIA published the sanction. Four years. Effective until September 2029.

Somani is 26, an Indian national. His career-high ranking was No. 256 in doubles. A sample returned a positive result for trimetazidine at a lower-tier event in Astana, Kazakhstan. His explanation: contaminated food, caused by a family member's medication finding its way into what he ate.

For the next four years, Somani cannot play, cannot coach, and cannot attend any event organized by World Tennis, the WTA, the ATP, the Grand Slams, or any national federation. Being banned from competing is one thing. Being banned from being present is another entirely.

If that explanation sounds familiar, it is because it has already been written, on the same kind of paper, through the same line of reasoning, ending in the same four-year outcome. Kamila Valieva, Beijing 2026. Sun Yang, 2026. And now Somani, 2026.

The point is not whether he cheated. The point is that a legal argument has become a standardized product, packaged, distributed, and consumed across the professional tennis system — while the ability to pay for that product is distributed with extreme inequality.

Context: One Substance, Three Nationalities, Eleven Years

Trimetazidine is a cardiac medication used to treat angina. Its mechanism optimizes the energy metabolism of heart muscle cells under oxygen deprivation — meaning it helps muscle work more efficiently in low-oxygen conditions. For an endurance athlete, that is a gift. It sits in WADA's S4 category, hormones and metabolic modulators.

In 2026, Sun Yang, the Chinese swimming star, tested positive for trimetazidine and received a three-month suspension. At the time the substance had just been added to the prohibited list, and the defense revolved around cardiac medication he used for health reasons.

Eight years later came Valieva. Her sample from the Russian national championships in December 2026 returned an adverse finding for trimetazidine. At the Beijing 2026 Winter Olympics, the story exploded while she was the gold-medal favorite in the women's singles. Her lawyers argued the substance entered her body through a strawberry dessert prepared by her grandfather, who used trimetazidine for a heart condition and shared the same knife and cutting board. The Court of Arbitration for Sport rejected it, and Valieva received four years.

With Somani, the motif returned almost verbatim. A family member on heart medication. The medication entering the food. Somani eating it. His body testing positive. And this time, the ITIA tribunal called it "scientifically implausible."

Eleven years, three cases, three continents, one substance. This is not a run of coincidences. This is a line of argument that has reached legal maturity.

The Thing to Measure Is Not the Substance, But the Structure of the Defense

Since I began writing about professional tennis, I have carried a persistent suspicion about how the media handles doping cases. They always ask the wrong question. They ask whether the athlete is guilty. The right question is where this defense was manufactured, at what price, and who can afford the premium version.

I call this operation diving the data: taking a string of seemingly disconnected facts from three sports, three legal systems, and three income brackets, then holding them against the same ruler to find the variable that is actually moving.

In Somani's case, that variable is not trimetazidine. It is the legal infrastructure a No. 256 doubles player can access.

Line the three cases up.

| Criterion | Sun Yang (2026) | Kamila Valieva (2026) | Parikshit Somani (2026) | |---|---|---|---| | Substance | Trimetazidine | Trimetazidine | Trimetazidine | | Defense | Cardiac medication use | Grandfather's dessert | Food cooked at home | | Adjudicating body | Swimming authority / WADA | CAS | ITIA tribunal | | Sanction | 3 months | 4 years | 4 years | | Rank / profile | World No. 1 | Olympic gold favorite | No. 256 in doubles | | Media infrastructure | Global | Global | Almost none |

This table says something the rankings never say: the same substance, the same argument, but three entirely different levels of defense capability.

The interesting column is the fourth. Sun Yang escaped with three months because his defense had a concrete medical basis and the timing of the violation was unclear under the rules then in force. Valieva lost four years because her defense could not stand against the scientific burden of proof. Somani lost four years because his defense could not stand against that same burden, but at a tier of the sport where almost no one is watching the quality of the argument.

The issue is not the length of the ban. The issue is the level of preparation behind that ban.

The Industry of Contamination Defenses

One thing must be said clearly before going further: a contamination defense is not always fabricated. Food contamination is real. It happens. Laboratories record it. Tribunals have accepted it, and have cleared athletes on that basis.

But when a scientifically valid argument is used over and over as a default card, it changes in nature. It stops being a truth and starts being a tactic.

Three features indicate that a defense has entered the industrial phase.

First, modularity. An industrialized defense can be taken apart and reassembled. You take a substance on the prohibited list. You find a relative who uses medication containing it. You construct a shared-living scenario — kitchen, knife, cutting board, spoon, ice tray. You add a nutrition or pharmacology expert for authentication. You assemble it and file. Nothing in this process requires the specific truth of the case.

Second, standardized language. Defense filings in food-transmission cases use nearly identical sentence structures: indirect contamination chains, absence of subjective intent, concentration levels compatible with therapeutic dosage. This language does not describe an experience. It describes a format.

Third, asymmetric cost. And this is the crux.

A contamination defense only has value if the tribunal accepts that the source has been proven. To prove that, the athlete must reconstruct the causal chain: which product, what dosage, when it was absorbed, whether the measured concentration in the urine sample matches the pharmacokinetic model, whether the knife, the board, and the cook's hands constitute a plausible transmission vector.

That is a process requiring an independent analytical laboratory, a pharmacokinetics expert, data modeling, the relative's medical records, and a lawyer who understands every clause of the World Anti-Doping Code. At the top tier, that cost sits inside the operating budget of a national federation or an Olympic team. At No. 256 in doubles, it is entirely out of reach.

How much does a No. 256 doubles player earn in a year? The figure swings by season, but at the ITF World Tennis Tour level, most prize money falls below what it takes to cover travel, hotels, food, and a traveling coach. Many players at this tier spend more than they earn. They live on family money, small sponsorships, or earnings from local events.

Which means: a No. 256 player can receive a four-year ban because his defense was not scientifically strong enough, while the very ability to make that defense scientifically strong is something he cannot afford to buy.

This is not a personal tragedy. It is a system design flaw.

Who Is Actually Protecting Whom

When arguing about doping, fans tend to split into two camps: those who believe the athlete and those who believe the regulator. Both camps overlook the real structure of the game. The regulator is not facing off against the athlete. The regulator is facing off against a legal services market that grows every year.

Look at how the ITIA operates. It is an independent body administering the integrity program for professional tennis, covering sample collection, investigation, prosecution, and coordination with an independent tribunal. That structure is designed to separate investigation from adjudication, a sound governance principle.

But every system with a finite budget runs on an implicit logic: it allocates resources where reputational risk is greatest. That means cases at the Grand Slam level, the Olympic level, the star level receive the highest intensity of handling. Cases at the Astana level, the low-tier level, the unknown-player level pass in silence, unless a press release is pushed out, as happened with Somani.

I am not saying this to accuse the ITIA. I am saying it to describe the structure. A system without an infinite budget will always protect reputational assets first and fairness second. That is the rule for every professional sports organization, from the ITIA to football federations, from Grand Slam organizers to continental tournaments.

An Experiment I Ran and Failed

I know what it feels like to be flattened by a system larger than yourself, even at a much smaller scale. When I was 16, I built a statistical model in Excel to predict the results of a V.League football club's matches, based on data from 120 previous games. I published the model on a forum, arguing the team should switch to a back three and press high. In the following two matches, the team conceded seven goals.

The online community did not spare me. But I did not take the post down. I wrote another two-thousand-word piece defending the argument, not because I believed I was right, but because I wanted to understand why I was wrong. I trust data, but I trust more the mistakes that data cannot measure.

The difference between me and Somani is this: when I was wrong, I lost credibility on a forum. When he is wrong, he loses four years of his career and possibly the rest of his life attached to the sport he spent his youth pursuing.

That is why I do not write about doping in moral terms. I do not have enough facts to say whether Somani is guilty or innocent. But I have enough facts to say the system has created a playing field where two people making the same argument receive starkly different treatment, depending on their bank balance.

Why Trimetazidine Is the Ideal Substance for This Argument

There is a technical detail worth pausing on. Not every banned substance suits a contamination defense. Trimetazidine suits it surprisingly well, for three reasons.

First, it is a common prescription drug. Many middle-aged and older people across many countries take it for cardiac issues. That means any household could plausibly contain a box of medication with this substance. A relative with a heart condition is not a rare circumstance. It is a common one.

Second, it has a short half-life. The substance clears the body relatively quickly, which turns the task of determining the timing and dosage of absorption from a single sample into a complex pharmacokinetic problem. The more complex it is, the more room the argument has.

Third, it has no permitted threshold. For some substances, regulators set a specific concentration threshold, and only exceeding it counts as a violation. Trimetazidine is not in that group. Any detectable concentration is enough to open a case.

Together, these three features produce a substance whose presence in a sample does not automatically answer the question of intent. And when the question of intent goes unanswered, the full weight of the case falls on the quality of the defense.

Which means it falls on money.

The Causal Chain Nobody Wants to Draw

Let me draw this chain slowly, because it is the entire argument.

A young player at the low tier needs money to compete internationally. He plays in Kazakhstan, in India, in Tunisia, in Turkey, at events where the prize money does not cover the plane ticket. He eats at the cheapest places. He stays at the cheapest places. He is exposed to food that is not controlled as tightly as in an Olympic village.

Meanwhile, he gets tested. The testing system does not distinguish No. 256 from No. 26. A sample is a sample. A positive in Astana carries the same legal weight as a positive in Melbourne.

But when he tests positive, he enters an appeals process whose success depends directly on the resources he can mobilize. He needs to prove the contamination source. He needs a pharmacokinetic model. He needs experts. He needs lawyers.

And here the chain splits into two branches. Branch one: he manages all of the above, proves the contamination source, and becomes a case cited by law firms as precedent. Branch two: he fails, the tribunal calls his argument "scientifically implausible," and he takes four years.

Both branches are called fairness.

The Debate Room and the Lesson of Narrowing

I once set up a small group called a debate room around the time of Euro 2026, when stadiums sat empty because of the pandemic. We experimented with analyzing matches through the sound of players' applause, since there were no fans in the stands. The group collapsed after three weeks. The cause was not a shortage of ideas but a surplus of them at once: tactics, finance, psychology, all opened simultaneously. The debate room did not die of silence. It died of a missing focal point.

I tell this story to say that the Somani case also has a focal point, and that focal point is buried under the doping headline. The focal point is not the question of guilt. The focal point is the economic structure of the right to self-defense in professional sport.

When a No. 256 doubles player walks into a hearing room, he does not walk into a fair room between two parties with equivalent resources. He walks into a process where the other side has the budget of an entire tournament system, and he has a relative with a heart condition and a kitchen.

The Counterintuitive Angle: The Victim Is Not the Athlete

Here I want to bet on an angle most doping coverage never touches.

When a No. 256 player is suspended for four years, the default public reaction is sympathy or suspicion. Both are emotional reactions, and both miss the structure. But if I had to pick a loss with more systemic meaning, I would say the biggest loser is not Somani.

The biggest loser is the legitimacy of the anti-doping testing system at the lower tier.

Imagine the consequences if what I just described is true. A system where the quality of defense depends on money means that at the low tier, any athlete who tests positive has almost no chance of a successful appeal. That creates two kinds of risk at once.

Risk one: those who are genuinely contaminated by accident will be wrongly convicted at a higher rate at the low tier than at the top. Risk two, more serious: those who genuinely cheat at the low tier will realize that defending themselves is pointless, and will therefore optimize their cheating behavior rather than abandon it.

In other words, when the right to self-defense becomes a luxury good, the system does not merely lose fairness in the moral sense. It loses effectiveness in the technical sense. It stops deterring the right people and starts deterring the wrong ones.

This is why I do not trust pieces that revolve only around the guilt question. It is the easiest question to answer and the most useless to analyze.

What the ITIA Actually Announced

It is worth being clear about what is in the document and what is not, because factual discipline is the only thing I can hold onto when writing about a case for which I do not have the full file.

The ITIA said an independent tribunal banned Somani until September 2029. The ITIA said Somani explained the positive result as contamination by food prepared by a family member who used medication containing trimetazidine. The ITIA said that at the August hearing, Somani's defense did not prove the source of the alleged contamination. The tribunal concluded that the food contamination theories were "scientifically implausible," "highly speculative," and "unconvincing."

The ITIA did not publish details of the concentration measured in the sample. The ITIA did not publish whether Somani had legal representation at the hearing. The ITIA did not publish the cost of the investigation, nor the ratio between samples collected and cases prosecuted at the lower tier.

Those gaps are not technical details. They are missing data, and missing data always favors the side with more resources in telling the story.

What I Still Do Not Know, and That Is Fine

I do not know whether Somani ate food contaminated with trimetazidine that day. I do not have the sample, the lab report, the pharmacokinetic table, or his relative's medical records. Without those, any conclusion about guilt or innocence is an emotional probability dressed in numerical clothing.

Three things I do know.

I know trimetazidine is a threshold-free banned substance, commonly used for cardiac treatment, and on the prohibited list since 2026.

I know there have been three discrete cases over eleven years using the same substance with the same type of argument: contamination from a relative in a domestic setting.

I know the sanctions in all three cases reflect not the level of suspicion but the level of provability.

Those three facts are enough to draw a model. And that model says the problem in lower-tier professional tennis is not a lack of anti-doping rules. The problem is that anti-doping rules are enforced on a playing field where only one side knows the rules.

So What, for the Fan

The ordinary fan has no access to ITIA hearings, cannot read the full ruling, cannot see the evidence file. They get one line of news: a 26-year-old Indian player suspended four years for testing positive for trimetazidine.

That line is true. And that line is useless.

When following a doping case, fans should ask three questions different from the ones the press asks. Does this athlete have the resources to prove a contamination source, or only enough to present a hypothesis? Did the tribunal reject the defense because the argument was wrong, or because it was not technically strong enough? And if this athlete were ranked in the top 20, would the result be different?

No one can answer the third question with data. But asking it is itself an act of analysis.

Closing One Case, Opening a Template

The sanction handed to Parikshit Somani runs until September 2029. By then he will be 30. In doubles, 30 is still a playable age. Which means that in theory the door is not fully shut. But four years without playing, without coaching, without being allowed to appear at any event in the system means that door is no longer a door. It is a wall with a handle attached.

What I take from this case is not a judgment about Somani. What I take is an awareness that trimetazidine has become the representative substance for a new kind of dispute in professional sport: a dispute over the quality of legal infrastructure, disguised as a dispute over science.

And when a scientific dispute is really a budget dispute, the weaker side loses before the hearing begins.

I trust data. But the data here is a string of silences: the number of low-tier cases not published, the cost of defense not published, the number of athletes who give up before appealing not published. Those three empty columns are the strongest conclusion in this entire case.